ID   MYL-R
AC   CVCL_D203
DR   Wikidata; Q54907177
RX   PubMed=17432977;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI_45783; Imatinib (Gleevec; STI571).
CC   Sequence variation: Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=17432977).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_D202 ! MYL
SX   Female
AG   24Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 19-12-24; Version: 14
//
RX   PubMed=17432977; DOI=10.1111/j.1600-0609.2007.00835.x;
RA   Ito T., Tanaka H., Kimura A.;
RT   "Establishment and characterization of a novel imatinib-sensitive
RT   chronic myeloid leukemia cell line MYL, and an imatinib-resistant
RT   subline MYL-R showing overexpression of Lyn.";
RL   Eur. J. Haematol. 78:417-431(2007).
//